Valiant Laboratories Complete Financial Statements
In FY2026, Valiant Laboratories (VALIANTLAB) reported revenue ₹92 Cr, net profit ₹2 Cr and EPS ₹0.32, with a net profit margin of 2.2% and ROE of 0.9%. Full financial statements from FY2022 to FY2026 (5 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Explore Valiant Laboratories intrinsic price to estimate fundamental worth using multiple valuation models.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
VALIANTLAB Revenue, Net Profit & EBITDA — Year-on-Year Growth
VALIANTLAB YoY (Mar 2025 vs Mar 2026) — revenue +64.3%, net profit +100.0%, EBITDA +150.0%, expenses +61.1%. Review VALIANTLAB P/E comparison to evaluate earnings-based valuation against sector peers.
VALIANTLAB Income Statement — Revenue, EBITDA & Net Profit
Valiant Laboratories revenue ₹92 Cr, EBITDA ₹5 Cr, net profit ₹2 Cr, EPS ₹0.32 (2026) — net profit margin 2.2%. For live price, earnings ratios and company overview, see VALIANTLAB stock price BSE.
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Jun 2022 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 92 | 47 | 56 | 48 | 53 | 25 | 33 | 22 | 37 | 63 | 92 | 54 | 42 | 84 | 72 |
| Expenses | 87 | 46 | 54 | 44 | 53 | 28 | 35 | 21 | 35 | 61 | 81 | 48 | 47 | 79 | 61 |
| EBITDA | 5 | 1 | 2 | 3 | 0 | -3 | -2 | 0 | 2 | 2 | 10 | 6 | -5 | 4 | 11 |
| Operating Profit Margin % | 5.00% | 0.00% | 7.00% | 5.00% | -2.00% | -31.00% | -15.00% | -13.00% | 2.00% | -2.00% | 10.00% | 7.00% | -16.00% | 5.00% | 14.00% |
| Depreciation | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 |
| Interest | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | 0 | 1 | 3 | -3 | -4 | -3 | 0 | 2 | 1 | 10 | 6 | -5 | 4 | 10 |
| Tax | -1 | 0 | 0 | 1 | 4 | 1 | -1 | 0 | -1 | 0 | 2 | 2 | -2 | 1 | 3 |
| Net Profit | 2 | 0 | 1 | 2 | -7 | -5 | -1 | -1 | 2 | 1 | 8 | 4 | -4 | 3 | 8 |
| Earnings Per Share (₹) | 0.32 | 0.04 | 0.16 | 0.42 | -1.30 | -1.09 | -0.33 | -0.13 | 0.54 | 0.24 | 2.41 | 1.31 | -0.81 | 1.65 | 4.70 |
VALIANTLAB Balance Sheet — Assets, Liabilities & Shareholders' Equity
VALIANTLAB total assets ₹401 Cr, total equity ₹234 Cr, total liabilities ₹ Cr (2025) — ROE 0.9%.
| Particulars | 2025 | 2024 | 2023 |
|---|---|---|---|
| ASSETS | |||
| Total Assets | 401 | 343 | 213 |
| Current Assets | 193 | 226 | 151 |
| Fixed Assets | 48 | 50 | 48 |
| Capital Work in Progress | 156 | 43 | 1 |
| Investments | 0 | 38 | 34 |
| Other Assets | 197 | 212 | 130 |
| LIABILITIES | |||
| Total Liabilities | |||
| Current Liabilities | 107 | 77 | 62 |
| Non-Current Liabilities | |||
| SHAREHOLDERS' EQUITY | |||
| Total Equity | 234 | 237 | 101 |
| Share Capital | 44 | 44 | 33 |
| Reserves & Surplus | 191 | 193 | 68 |
VALIANTLAB Cash Flow Statement — Operating, Investing & Financing
Valiant Laboratories operating cash flow ₹1 Cr, investing ₹-53 Cr, financing ₹45 Cr, net cash flow ₹-7 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 |
|---|---|---|---|
| Operating Activities | 1 | 2 | 56 |
| Investing Activities | -53 | -144 | -55 |
| Financing Activities | 45 | 152 | -1 |
| Net Cash Flow | -7 | 11 | 0 |